1. World Health Organization International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. [Updated: 2017]. Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx [Accessed: Aug 25, 2017]
2. National Cancer Institute Surveillance, Epidemiology and End Results Program. Cancer Stat Facts: Colon and Rectum Cancer [Internet]. 2017. Available from: https://seer.cancer.gov/statfacts/html/colorect.html [Accessed: Aug 25, 2017]
3. Cancer Research UK. Bowel Cancer Incidence Statistics [Internet]. Feb 15, 2017. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/incidence [Accessed: Aug 25, 2017]
4. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncology. 2014;15(10):1065-1075. DOI: 10.1016/S1470-2045(14)70330-4
5. Van Cutsem E, Nordlinger B, Adam R, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. European Journal of Cancer. 2006;42(14):2212-2221. DOI: 10.1016/j.ejca.2006.04.012